TAG:
laboratories
Specialty Laboratories, Enterix, Medicare, Blue Cross/Blue Shield Association
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
SPECIALTY LABORATORIES REPORTS THIRD QUARTER FINANCIAL PERFORMANCE THIRD QUARTER FINANCIAL REPORTS for Specialty Laboratories, Inc. show that the company is returning to a more normal routine, following the two unusual and unrelated events which hit it during 2002. Special…
Market Demand for Pathologists Shifts Toward Specialization
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
Bio-Reference Labs An Example Of How Regional Labs Can Grow
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
IT’ S QUARTERLY EARNINGS TIME, which makes it possible to evaluate trends in the laboratory services marketplace by looking at the performance of public laboratory companies. Because of their large size and market dominance, the two national laboratory companies are closely watched to see how they…
Mergers Create Two Huge National Health Insurers
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
ANOTHER ROUND OF CONSOLIDATION among health insurers has created a new “biggest in the nation” company and boosted the size of the second largest health insurance company. On October 28, in separate announcements that were just 30 minutes apart, Anthem Inc. disclosed it would pa…
“November 10, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
Has the disappearance of much despised closed panel HMOs eased the financial woes of physicians? Apparently not, according to a recent study. Medical groups are losing money. Nationwide, the average loss-per-physician by medical groups was $3,977. In the 2003 survey, 25,784 physicians responded, a 26…
OIG Moves to Address “Usual Charge” Issue
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: Federal regulators are taking another crack at defining “usual charges.” Language in the proposed rules published last month precisely defines which payers should be included in determining “usual charges” and what charge basis to use for specific payers. Once effecti…
No Disruptive Technology In Lab Industry’s Future
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: As new diagnostic technologies move through the development pipeline and into widespread clinical use, the scientific knowledge and skill sets needed by laboratory staff and management will change. The emphasis in laboratory medicine will evolve to include more molecular tech…
Looking at Fast-Growth And Slow-Growth Areas In Diagnostic Testing
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
CEO SUMMARY: This exclusive intelligence briefing predicts how specific new technologies may drive changes in the laboratory-testing marketplace during the next five years. The key message is that change is expected to be incremental, not disruptive—given the technology known to be in d…
Two Blood Brothers Ramp Up Marketing of New Lab Assays
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
GROWTH IN SPECIMEN VOLUME and revenues is the major challenge at the nation’s two largest laboratory corporations. How Laboratory Corporation of America and Quest Diagnostics Incorporated solve this problem will affect and influence every remaining clinical labora…
“October 20, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
Here’s a reminder that corporate fraud didn’t bypass healthcare. Last week Albert Bergonzi, former Executive Vice President of McKesson/HBOC, pled guilty to violations of securities laws. He admitted that he had “cooked the books” around the time of HBOC’s acquisition by Mc…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized